Accelus vs Revvity
Side-by-side comparison of AI visibility scores, market position, and capabilities
Accelus is a global leader in expandable interbody spinal implant technology with 32,000+ cages implanted in 25 countries; secured new equity financing in May 2025 led by Concord Health Partners;
About
Accelus is a medical device company specializing in expandable interbody spinal implant technology. Its products include bi-directional expandable cages designed to address height, lordosis, and weight parameters during spinal fusion surgery, providing the structural stability of monolithic implants while enabling minimally invasive delivery. With more than 32,000 cages implanted across 25 countries, Accelus has established a strong international commercial presence in the spine surgery market.
Revvity (RVTY) reported ~$2.9B revenue in FY2024. Life science tools and diagnostics company providing instruments, reagents, and software for genomics, newborn screening, and drug discovery. HQ: Waltham, MA.
About
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provider of solutions for reproductive health, genomics, and applied markets. The company operates in two segments: Life Sciences (analytical instruments, reagents, software for pharmaceutical and academic research) and Diagnostics (immunoassay and molecular diagnostic systems for clinical and screening applications). Revvity is the global leader in newborn screening, processing the tests that check newborns for metabolic and genetic disorders shortly after birth.
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.